Form 4: Oruka Therapeutics GC Executes Sell-to-Cover Transaction

General Counsel Paul T. Quinlan sold 733 shares of Oruka Therapeutics to satisfy tax obligations related to RSU vesting.

Summary

• Paul T. Quinlan, General Counsel of Oruka Therapeutics, Inc., sold 733 shares of common stock.
• The transaction occurred on June 15, 2026, at a price of $69.69 per share.
• Following the transaction, the reporting person maintains beneficial ownership of 31,034 shares.
• The sale was conducted via an automatic, non-discretionary sell-to-cover procedure.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was mandatory and non-discretionary for tax purposes.

Positives

• The transaction was purely administrative to cover tax liabilities, indicating no change in long-term investment sentiment.

Negatives

• Reduction in direct share ownership by a key executive.

Risks

• None identified; this is a routine tax-related transaction.

Future Outlook

No forward-looking guidance provided in this filing.

Management Comments

• The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that sell-to-cover transactions are standard corporate practice for executives to manage tax liabilities upon the vesting of equity awards and do not typically signal a change in management's outlook on company performance.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation and tax management practices observed across the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related sell-to-cover.

Next Steps

• None

Key Dates

Keywords

Oruka Therapeutics, ORKA, Insider Trading, Form 4, Sell-to-cover, Executive Compensation